Local side effects of subcutaneous and stimulation in in vitro fertilization: A prospective, randomized study

Fertility and Sterility

Volumn 69, Issue 5, 1998, Pages 836-840

  Engmann, Lawrence ^a   Shaker, Adel ^a,b   White, Emma ^a   Bekir, Jinan S ^a   Jacobs, Howard S ^a,c   Tan, Seang Lin ^a,d  

^a London Women's Clinic   (United Kingdom)

^b Ross Hall Hospital   (United Kingdom)

^c MIDDLESEX HOSPITAL   (United Kingdom)

^d ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Gonadotropins; In vitro fertilization; Intramuscular; Local side effects; Normegon; Subcutaneous

Indexed keywords

CHORIONIC GONADOTROPIN; FOLLITROPIN; GONADORELIN AGONIST; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG MIXTURE; EDEMA; ERYTHEMA; FEMALE; FERTILIZATION IN VITRO; HUMAN; INCIDENCE; INJECTION PAIN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; OVARY HYPERSTIMULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADOLESCENT; ADULT; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; MENOTROPINS; OVARY; PROSPECTIVE STUDIES;

EID: 0032079511     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(98)00043-0     Document Type: Article

References (18)

1. 1. Giudice E, Crisci C, Eshkol A, Papoian R. Composition of commercial gonadotropin preparations extracted from human post-menopausal urine: characterization of non-gonadotropin proteins. Hum Reprod 1994;9:2291-9.
2. 2. Saal W, Happ J, Cordes U, Baum RP, Schmidt M. Subcutaneous gonadotropin therapy in male patients with hypogonadotropic hypogonadism. Fertil Steril 1991;56:319-23.
3. 3. Jones TH, Darne JF. Self-administered subcutaneous human menopausal gonadotropin for the stimulation of testicular growth and the initiation of spermatogenesis in hypogonadotropic hypogonadism. Clin Endocrinol 1993;38:203-8.
4. 4. Rossmanith WG, Sterzik K, Wolf AS. Initial experiences with subcutaneous pulsatile human menopausal gonadotropin administration: successful induction in patients with polycystic ovarian disease. Int J Fertil 1991;32:460-6.
5. 5. Nakamura Y, Yoshimura Y, Yamada H, Ubukata Y, Yoshida K, Tamaoka Y, et al. Clinical experience in the induction of ovulation and pregnancy with pulsatile subcutaneous administration of human menopausal gonadotropin: a low incidence of multiple pregnancy. Fertil Steril 1989;51:423-9.
6. 6. Schmoutziguer APE, Van Kooy RJ, Koudstaal J, Zonneveld P, Nan PM, Te Velde E. Subcutaneous administration of urinary gonadotropins: efficacy and safety in in-vitro fertilization. J Obstet Gynaecol 1996;16:409-13.
7. 7. Zaidi J, Pittrof R, Shaker A, Kyei-Mensah A, Campbell S, Tan SL. Assessment of uterine artery blood flow on the day of human chorionic gonadotropin administration by transvaginal color Doppler ultrasound in an in vitro fertilization program. Fertil Steril 1996;65:377-81.
8. 8. Tan SL, Royston P, Campbell S, Jacobs HS, Betts J, Mason B, et al. Cumulative conception and live birth rates after in vitro fertilization. Lancet 1992;339:1390-4.
9. 9. Tan SL, Maconochie N, Doyle P, Campbell S, Balen A, Bekir J, et al. Cumulative conception and live birth rates after in vitro fertilization with, and without, the use of the long, short and ultrashort regimens of the luteinizing releasing hormone agonist, buserelin. Am J Obstet Gynecol 1994;171:513-20.
10. 10. Tan SL, Waterstone L, Wren M, Parsons J. A prospective randomized study comparing aspiration only with aspiration and flushing for transvaginal ultrasound directed oocyte recovery. Fertil Steril 1992;57:356-60.
11. 11. Tan SL, Balen A, El-Hussein E, Mills C, Campbell S, Jacobs HS, et al. A prospective randomized study of the optimum timing of human chorionic gonadotropin administration after pituitary desensitization in in vitro fertilization. Fertil Steril 1992;57:1259-64.
12. 12. Li TC, Hindle JE. Adverse local reaction to intramuscular injections of urinary-derived gonadotropins. Hum Reprod 1993;8:1835-6.
13. 13. Dore PC, Rice C, Killick S. Human gonadotropin preparations may cause allergic reaction. Br Med J 1994;308:1509.
14. 14. Biffoni M, Battaglia A, Borelli F, Cantelmo A, Galli G, Eshkol A. Allergenic potential of gonadotrophic preparations in experimental animals: relevance of purity. Hum Reprod 1994;9:1835-6.
15. 15. Odink J, Zuiderwijk PBM, Schoen ED, Gan RA. A prospective, double-blind, split-subject study on local skin reactions after administration of human menopausal gonadotropin preparations to healthy female volunteers. Hum Reprod 1995;10:1045-7.
16. 16. Howles CM, Loumaye E, Giroud D, Luyet G. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicenter European phase III study. Hum Reprod 1994;9:424-30.
17. 17. Out HJ, Reimitz PE, Coelingh Bennik HJT. A prospective, randomized study to assess the tolerance and efficacy of intramuscular and subcutaneous administration of recombinant follicle-stimulating hormone (Puregon). Fertil Steril 1997;67:278-83.
18. 18. Recombinant Human FSH Group. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertil Steril 1995;63:77-86.